Orchid Pharma Ltd
NSE:ORCHPHARMA
Orchid Pharma Ltd
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Sales Decline: Sales fell 5% year-on-year for Q3 to INR 207 crores, and are down 16% for the 9-month period, reflecting a challenging global antibiotics market.
Margin Pressure: EBITDA margin dropped sharply to 6% from 17% last year, mainly due to depressed pricing in key antibiotic molecules and a weaker regulated market mix.
Cost Control: Non-employee costs cut by 10% over 9 months; R&D investment increased to 1.5% of sales to support differentiated products.
Exblifep Progress: Early commercial launches in Spain, Italy, UAE, and Kuwait; more licensing deals expected soon, with sales in Europe up over 200% on a small base.
7ACA Project On Track: Major construction milestones achieved; mechanical completion targeted for September, expected to improve cost competitiveness.
AMS Division Improvement: EBITDA drag from AMS reduced, with sales steadily rising and better operating leverage.
Outlook Cautiously Positive: Some recovery signs in January, but pricing remains uncertain; management expects gradual improvement from new products, launches, and cost discipline.
Strong Balance Sheet: INR 75 crores cash on hand, unused working capital lines, and INR 170 crores drawn from a planned INR 450 crores debt for 7ACA project.
